

Special Issue

Inflammasomes as the Target of Pharmacotherapy

Message from the Guest Editors

As a sensor of infections and external stimuli, inflammasomes play a key role in the pathological process of various diseases. Inflammasomes are intracellular multimeric complex molecules including: i) canonical inflammasomes (NLRP3, NLRC4, and AIM2) that serve as a platform to engage pro-caspase-1, which becomes active caspase-1 and processes pro-interleukin-1 β (IL-1 β) and pro-IL-18 to generate their active forms, inducing pyroptosis, a pro-inflammatory form of cell death 2,3-5; and ii) noncanonical inflammasomes that activate caspase-11 (mouse) or caspase-4/5 (human) without cleaving pro-IL-1 β 1,6. Available compounds act mainly by inhibiting the products of inflammasome activation, but given the lack of effective drugs in the therapy of different inflammatory chronic conditions, it is becoming particularly pressing to understand and provide a potentially practical pharmacological approach for treating NLRP3-driven diseases. In this Special Issue, we aim to gather research from experts in the field that highlights therapeutic agents and strategies to identify future discoveries and therapies for “inflammasomes”-mediated inflammatory disorders.

Guest Editors

Dr. Francesca La Rosa
IRCCS Fondazione Don C. Gnocchi, ONLUS, 20148 Milan, Italy

Dr. Marina Saresella
IRCCS Fondazione Don C. Gnocchi, ONLUS, 20148 Milan, Italy

Deadline for manuscript submissions

closed (20 December 2023)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/130667

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)